EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Exploring novel perspectives on eosinophilic inflammation in severe asthma

Claudio Candia, Pasquale Ambrosino iD, Silvestro E D'Anna, Andrea Motta, Mauro Maniscalco iD

Biomarkers in Medicine · 2024

DOI: 10.2217/bmm-2023-0801 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomarkers in Medicine, 2024. Verfasst von Claudio Candia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine & Surgery, Federico II University, Naples, 80131, Italy. Hauptthemen laut MEDLINE: Asthma, Eosinophils, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two recent articles by the same research group documented that patients with severe eosinophilic asthma exhibit an increased proportion of a subtype of eosinophils, namely CD62Llow inflammatory eosinophils (iEos) and identified an intriguing correlation between such iEos and asthma control scores. Moreover, CD62Llow iEos were reduced after treatment with the anti-IL-5 monoclonal antibody mepolizumab. In the future, we believe that eosinophil subtypes could represent a useful biomarker in severe eosinophilic asthma, helping clinicians characterize patient endotypes and monitoring the response to biological drugs. Patients with severe eosinophilic asthma (SEA) have an increased proportion of a subtype of eosinophils, CD62Llow inflammatory eosinophils (iEos), which are reduced after mepolizumab treatment. iEos might represent a novel useful biomarker in SEA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaEosinophilsInflammationHumansBiomarkersAntibodies, Monoclonal, HumanizedEosinophiliaInterleukin-5Severity of Illness Index

Stichwörter der Autor:innen

biomarkerseosinophil subtypeseosinophilic inflammationoutcomerehabilitationsevere asthma

Substanzen

BiomarkersmepolizumabAntibodies, Monoclonal, HumanizedInterleukin-5

Autor:innen und Institutionen

  • Department of Clinical Medicine & Surgery, Federico II University, Naples, 80131, Italy.
  • Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Unit of Telese Terme Institute, 82037, Italy.
  • Institute of Biomolecular Chemistry, National Research Council, Pozzuoli, 80078, Italy.

ORCID-Profile: Pasquale Ambrosino, Mauro Maniscalco

Förderung

  • Ministero della Salute

Zitieren

APA

Candia, C., Ambrosino, P., D'Anna, S. E., Motta, A., & Maniscalco, M. (2024). Exploring novel perspectives on eosinophilic inflammation in severe asthma. Biomarkers in Medicine. https://doi.org/10.2217/bmm-2023-0801

Vancouver

Candia C, Ambrosino P, D'Anna SE, Motta A, Maniscalco M. Exploring novel perspectives on eosinophilic inflammation in severe asthma. Biomarkers in Medicine. 2024. doi:10.2217/bmm-2023-0801

BibTeX
@article{Candia2024,
  author = {Candia, Claudio and Ambrosino, Pasquale and D'Anna, Silvestro E and Motta, Andrea and Maniscalco, Mauro},
  title = {Exploring novel perspectives on eosinophilic inflammation in severe asthma},
  journal = {Biomarkers in Medicine},
  year = {2024},
  doi = {10.2217/bmm-2023-0801}
}
Kostenlos starten →